Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the antiviral effects of various treatments in adults aged 18 to 60 with early symptomatic influenza. This phase 2, multi-centre, adaptive platform trial compares several licensed influenza antiviral drugs and others with potential activity against the virus. The study aims to provide clear comparisons of antiviral activity to help guide treatment decisions and policy development. Participants may receive one of several antiviral drugs such as oseltamivir, favipiravir, zanamivir, baloxavir, molnupiravir, peramivir, laninamivir, or combinations of these medications. There is also a control group that receives no antiviral treatment except paracetamol for fever. Dosages and administration routes vary by drug and include oral, inhaled, and intravenous methods. The trial uses randomization to assign treatments, with at least 20% of participants assigned to the no treatment group. During the first five days, researchers will monitor the rate of viral clearance to assess antiviral activity. Additional measures include symptom relief and fever duration over 14 days. Participants will be closely followed up, with assessments including rapid antigen or PCR tests for influenza, symptom tracking, and safety monitoring. The total study period covers initial treatment and observation up to two weeks after starting treatment.
Actively Recruiting
Researchers are evaluating antiviral treatments for Respiratory Syncytial Virus RSV in low-risk adults aged 18 to under 65 years with early symptoms. This adaptive, open-label, randomized platform trial compares licensed and potential antiviral drugs against no treatment to assess their antiviral effects in patients with high viral loads and uncomplicated RSV infections. The study is funded by the Wellcome Trust and led by the University of Oxford. Participants will be randomly assigned to receive one of several antiviral drugs or no antiviral treatment. The study drugs include oral ribavirin, dosed based on weight three times daily for 5 days molnupiravir, given twice daily for 5 days and favipiravir, with a higher dose on Day 0 followed by a lower dose twice daily for 4 more days. The control group will receive supportive care without antiviral drugs. The trial maintains a minimum 20% allocation to no-treatment control throughout its duration. Participants will be involved for 28 days, during which researchers will measure the rate of viral clearance from Days 0 to 5, assess symptom relief and fever duration up to Day 14, and monitor for possible drug resistance. Evaluations include rapid antigen or PCR tests for RSV, symptom reporting, and clinical assessments. The study also tracks safety and antiviral effects, with follow-up visits planned to monitor progress and outcomes.
Actively Recruiting
Researchers are studying acute febrile illness in patients older than 28 days who live in rural areas of Laos, Myanmar, Thailand including the Thai-Myanmar border region, and Bangladesh. This observational study aims to describe the causes, clinical outcomes, and host biomarkers associated with these illnesses, which last 14 days or less. The study is part of a larger community-based network seeking to improve understanding and future interventions for febrile illness in low- and middle-income countries in South and Southeast Asia. The study involves two main parts Work Package A collects data from village health workers and local health facilities to understand the incidence and outcomes of febrile illness at the community level. Work Package B recruits patients seeking care at higher-level health facilities who may be more severely ill. In Work Package B, researchers collect various samples including venous blood and respiratory specimens for detailed diagnostic testing such as blood cultures, serological assays, molecular diagnostics, and host biomarker assays. Participants will be monitored for about one month to measure the prevalence of pathogens and recovery status. The study will analyze the association between host biomarkers and clinical outcomes to help create electronic decision-support tools for village health workers. These tools and other interventions will be tested later to improve assessment, triage, and treatment of patients with febrile illness. The total duration of participation and follow-up is approximately one month.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and acceptability of different doses of arpraziquantel in children aged 6 to 7 years who are infected with Opisthorchis viverrini. This parasite infection is common in young children and often goes untreated in current public health programs. The main goal is to understand how various doses affect the cure rate of the infection. Participants will receive a single oral dose of arpraziquantel at one of several ascending dose levels 20, 30, 40, 50, or 60 mg per kg of body weight. This dose-ranging trial is randomized and single-blind, with children assigned to one of these dosing groups. The study will assess the response after treatment and monitor safety at multiple time points. Children will be asked to provide stool samples before treatment and again 21 to 28 days afterward to measure cure rates and egg reduction rates. Safety and tolerability will be monitored at 3 hours, 24 hours, 21-28 days, and 42 days after treatment. The study participation involves follow-up assessments to collect these samples and monitor health, lasting up to about six weeks after treatment.
Actively Recruiting
Healthy Volunteer
Researchers are conducting a long-term observational study across three microbiology units in hospitals and community health systems in Thailand, Lao PDR, and Cambodia. The study focuses on melioidosis, aiming to understand how the environment, pathogen, and host interact to influence disease development and outcomes. It includes patients diagnosed with melioidosis, matched healthy controls, and residents of a high-risk community known as the Sandbox Village. Patients with melioidosis will be followed at six time points from hospital admission through one year post-discharge to collect clinical data on demographics, medical history, environmental exposures, treatment, adherence, and outcomes. Healthy controls matched by age, sex, and village will provide blood samples at enrollment and receive follow-up calls at 6 and 12 months. The Sandbox Village cohort will involve approximately 400 residents monitored intensively over 42 months, with periodic blood samples collected every two months to assess antibody responses. Participants will undergo various assessments including blood sampling, telephone follow-ups, and clinical data collection. Researchers will measure outcomes such as melioidosis development after exposure, mortality during the acute phase, and hospital readmissions for patients, while controls and community residents will be monitored for subclinical infections and environmental influences. The study spans up to 3.5 years for community participants and one year for patients and controls, with ongoing observation and data collection to better understand melioidosis risks and recovery.
Actively Recruiting
Researchers are evaluating antiviral treatments for adults with early symptomatic COVID-19 who have high viral loads but are at low risk of severe illness. This Phase 2 trial aims to develop and validate a way to measure how well these treatments reduce the amount of virus in the body. The study compares three types of interventionssmall molecule drugs, monoclonal antibodies, and dose adjustments for nirmatrelvirritonaviragainst a control group that receives no antiviral treatment. The trial is adaptive and is supported by the Wellcome Trust through the COVID-19 Therapeutics Accelerator. The treatments studied include various small molecule drugs like nitazoxanide, nirmatrelvirritonavir, hydroxychloroquine, atilotrelvirritonavir, metformin, and monoclonal antibodies such as sotrovimab and others as they become available. Some treatment arms have been closed after meeting stopping criteria. Participants are randomly assigned to receive one of the available antiviral drugs or no treatment, with at least 20% assigned to the control group. Dosages vary by drug and are typically administered over 5 to 7 days. Participants will be monitored closely over the first 14 days, with daily assessments of viral levels and symptoms. Researchers will measure how quickly the virus clears from the body compared to no treatment or positive control arms. Additional outcomes include fever resolution and symptom improvement. Participants must be able to walk unaided and agree to follow-up visits. The study runs until January 2027 and aims to determine optimal dosing and antiviral effectiveness in early COVID-19 infection.
Actively Recruiting
This research aims to understand how national medical oxygen strategies work and achieve impact at both national and local levels across different countries. It focuses on health systems and policy contexts in six countries involved in the Medical Oxygen Implementation program. The study seeks to involve policymakers, implementers, and medical oxygen users to identify challenges and find potential solutions to improve access to medical oxygen. Researchers also aim to generate new data and draw lessons that can inform national and global policy and practice. The study uses a mixed-methods design with three embedded parts stakeholder analysis, policy-implementation gap analysis, and comparative country case studies. It involves interviews with key informants from government, NGOs, professional associations, private sector, and civil society. The study is conducted in six countries and will be adapted to each context through ongoing collaboration with stakeholders. The research will run for four years and includes annual meetings to refine study topics and methods. Participants will take part in in-depth interviews focusing on national medical oxygen strategies over the four-year study period. Researchers will review policies, analyze program data, and compare findings across countries. The study will monitor how strategies are translated into action and their effects on oxygen service coverage. This involves collecting qualitative and quantitative data to better understand the implementation and challenges of medical oxygen programs within different health systems.
Actively Recruiting
This research aims to develop and evaluate a mobile health mHealth technology to help adult smokers in Lao Peoples Democratic Republic quit smoking cigarettes. The project addresses the high smoking rates among adults in Lao PDR, especially men, by adapting an automated, personalized smartphone-based intervention for smoking cessation. The study includes two main phases a formative research phase to adapt the intervention to local culture and language, and a randomized controlled trial RCT to test its effectiveness. The study involves two groups of adult smokers recruited from hospitals in Lao PDR. One group receives Standard Care, which includes brief advice to quit, self-help written materials, and a 2-week supply of nicotine patches. The other group receives Automated Treatment, which includes all Standard Care components plus a 26-week personalized smartphone program delivering interactive messages, images, and videos designed to support quitting. The intervention content is tailored to individuals quit attempts, coping skills, health conditions, and smoking status over time. Participants will complete baseline assessments and receive training on smartphone use if needed. Follow-up includes weekly smartphone assessments for six months for the Automated Treatment group and diet assessments for the Standard Care group. Researchers will monitor smoking status through biochemical confirmation and self-report at 3 and 12 months. The primary outcome is the rate of smoking cessation 12 months after enrollment. The study also aims to build local research capacity and improve tobacco cessation services in Lao PDR.
Actively Recruiting
Healthy Volunteer
Researchers are studying murine typhus and scrub typhus, diseases caused by bacteria transmitted by fleas and mites, respectively. These infections are difficult to diagnose and can vary widely in severity and mortality. The trial aims to understand how quickly these bacteria clear from the blood after treatment and to compare the effectiveness of two antibiotics, doxycycline and azithromycin, in treating these infections. Participants will receive either doxycycline, starting with a 200 mg loading dose followed by 100 mg every 12 hours for 3 days, or azithromycin, starting with a 500 mg loading dose followed by 250 mg daily for 2 days, then followed by 3 days of doxycycline. These treatments are given orally during the hospital stay. The study uses a randomized, parallel design to compare these two antibiotic regimens for murine typhus or scrub typhus. During the study, participants will have blood samples taken to measure bacterial clearance using PCR testing and to monitor drug levels in plasma and inside blood cells over time. Researchers will track fever resolution, adverse events, and evaluate diagnostic tests for accuracy. Follow-up visits will assess response to treatment and safety for up to 28 days. Total participation includes hospital stay and follow-up visits as scheduled by the study team.
Actively Recruiting
Researchers are investigating the optimal dose of tafenoquine for treating Plasmodium vivax malaria in Southeast Asia. This study compares the current recommended 300 mg dose of tafenoquine, which is less effective in this region, to a 50% higher dose. The trial also includes a comparison to high-dose primaquine in Indonesia, where primaquine is the standard care. The goal is to improve radical cure rates by reducing malaria recurrence. Participants will be randomly assigned to receive either the standard tafenoquine dose or a higher dose, both given as a single dose adjusted by weight bands. In Indonesia, a third group will receive high-dose primaquine daily for seven days. All participants will receive a schizonticidal agent such as chloroquine or artemether-lumefantrine alongside tafenoquine or primaquine. Drug administration will be directly observed to ensure adherence, and the treatments are given according to the national malaria guidelines. Participants will be followed daily until malaria parasites clear and then at several scheduled visits up to 4 months. These visits include blood tests, physical exams, and monitoring of adverse events and drug levels. If malaria recurs, treatment and follow-up restart as a new episode. The study measures include recurrence of infection by microscopy and molecular methods, adverse events, and drug levels over time. Data confidentiality and quality control procedures are in place, with a total participation duration of 4 months per episode.